Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

Giorgio V. Scagliotti,Rabab Gaafar,Anna K. Nowak,Jan P. van Meerbeeck,Nicholas J. Vogelzang,Ute von Wangenheim,Arsene-Bienvenu Loembe,Nassim Morsli,Derek Velema,Sanjay Popat

Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).

2016

Giorgio V. Scagliotti
Rabab Gaafar
Anna K. Nowak
Jan P. van Meerbeeck
Nicholas J. Vogelzang
Ute von Wangenheim
Arsene-Bienvenu Loembe
Nassim Morsli
Derek Velema
Sanjay Popat

TPS8574Background: Median overall survival (OS) is ~1 year with P/C, the standard front-line treatment for patients (pts) with unresectable MPM; additional improvement is needed. Nintedanib (N) is ...

Keywords:

Placebo
Pemetrexed
Mesothelioma
Cancer research
Cisplatin
Physical therapy
Medicine
Nintedanib
Lume
Gastroenterology
overall survival
pleural mesothelioma
Internal medicine
Pathology
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations